XML 49 R35.htm IDEA: XBRL DOCUMENT
v3.20.2

Fair Value Measurements - Additional Information (Details) $ in Thousands |  | 1 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Mar. 10, 2020 USD ($) | Oct. 31, 2020 USD ($) | Jun. 30, 2020 USD ($) | Sep. 30, 2020 USD ($) | Dec. 31, 2019 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Total unrealized gains recorded in accumulated other comprehensive income (loss) |  |  |  |  | $ 200 |  |
Derivative liability |  |  |  |  |  |  | $ 12,449
Reclassification of derivative liability to additional paid-in capital upon achievement of development milestone |  | $ 29,200 |  |  |  |  |
Maximum |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Securities contractual term |  |  |  |  | 1 year |  |
Humabs |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Specified clinical development milestones payment |  |  |  | $ 10,000 |  |  |
Estimated fair value of contingent consideration |  |  |  |  | $ 42,500 |  | $ 14,900
Humabs | Subsequent Event | SARS-CoV-2 Product |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Specified clinical development milestones payment |  |  | $ 10,000 |  |  |  |
Humabs | Measurement Input, Discount Rate | Commercial Milestones |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value contingent consideration measurement input |  |  |  |  | 0.11 | [1] | 0.13
Humabs | Measurement Input, Discount Rate | Maximum | Clinical and Regulatory Milestones |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value contingent consideration measurement input |  |  |  |  | 0.12 | [2] | 0.111
Humabs | Measurement Input, Discount Rate | Minimum | Clinical and Regulatory Milestones |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value contingent consideration measurement input |  |  |  |  | 0.10 | [2] | 0.077
Humabs | Measurement Input Expected Revenue Volatility | Commercial Milestones |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value contingent consideration measurement input |  |  |  |  | 0.60 | [1] | 0.55
TomegaVax |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Estimated fair value of contingent consideration |  |  |  |  | $ 9,500 |  | $ 2,700
TomegaVax | Measurement Input Risk Free Interest Rate | Maximum |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value embedded derivative estimated using discount rates |  |  |  |  |  |  | 0.017
TomegaVax | Measurement Input Risk Free Interest Rate | Minimum |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value embedded derivative estimated using discount rates |  |  |  |  |  |  | 0.016
TomegaVax | Measurement Input, Discount Rate | Maximum |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value contingent consideration measurement input | [3] |  |  |  | 0.002 |  |
TomegaVax | Measurement Input, Discount Rate | Minimum |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value contingent consideration measurement input | [3] |  |  |  | 0.000 |  |
TomegaVax | Expected Stock Price Volatility |  |  |  |  |  |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value contingent consideration measurement input | [3] |  |  |  | 0.85 |  |
Fair value embedded derivative estimated using discount rates |  |  |  |  |  |  | 0.81
[1] | Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments
[2] | Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.
[3] | Unobservable inputs were weighted based on the relative fair value of the underlying milestones.

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References No definition available. + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 + Details
Name: | us-gaap_DerivativeLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of input used to measure embedded derivative liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_EmbeddedDerivativeLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in an asset acquisition. + References No definition available. + Details
Name: | vir_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value reclassification of derivative liability to additional paid in capital upon achievement of development milestone. + References No definition available. + Details
Name: | vir_FairValueReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Specified clinical development milestones payment. + References No definition available. + Details
Name: | vir_SpecifiedClinicalDevelopmentMilestonesPayment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedRevenueVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |